Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Myositis × Rituximab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma 243 Lymphoma, Large B-Cell, Diffuse 231 Leukemia, Lymphocytic, Chronic, B-Cell 170 Lymphoma, Non-Hodgkin 164 Lymphoma, Mantle-Cell 148 Lymphoma, Follicular 148 Lymphoma, B-Cell, Marginal Zone 102 Leukemia 89 Burkitt Lymphoma 76 Waldenstrom Macroglobulinemia 74 Precursor Cell Lymphoblastic Leukemia-Lymphoma 74 Lymphoma, B-Cell 52 Hodgkin Disease 49 Recurrence 46 Lymphoma, Large-Cell, Immunoblastic 41 Leukemia, Myeloid, Acute 20 Myelodysplastic Syndromes 18 Lymphoma, Large-Cell, Anaplastic 17 Intraocular Lymphoma 14 Hematologic Neoplasms 14 Dendritic Cell Sarcoma, Interdigitating 14 Multiple Myeloma 13 Neoplasms 12 Leukemia, Hairy Cell 12 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11 Neoplasms, Plasma Cell 10 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10 Leukemia, Prolymphocytic 9 Leukemia, Myelomonocytic, Chronic 9 Leukemia, Myeloid, Accelerated Phase 9

Interventions

Immune Checkpoint Inhibitors 2 fludarabine 1 Rituximab 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00774462 2012-12-11

FORCE

Assistance Publique - Hôpitaux de Paris

Phase 2 Completed

Myasthenia Gravis, Myositis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡